Moderna (NASDAQ:MRNA) Shares Up 6.7% – What’s Next?

Moderna, Inc. (NASDAQ:MRNA) shares shot up 6.7% on Tuesday. The company traded as high as $243.98 and last traded at $242.08. Approximately 16,754,052 shares changed hands during trading, an increase of 35% from the average session volume of 12,391,332 shares. The stock had previously closed at $226.89.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Investors are positioning ahead of a Saturday presentation of detailed Phase 3 data for Moderna’s personalized melanoma vaccine, developed with Merck. Positive results could strengthen the company’s emerging oncology business and support a higher valuation. Moderna Jumps 7% While Melanoma Vaccine Data Looms
• Positive Sentiment: Moderna’s cancer-treatment pipeline is drawing heavy buying as the market focuses on upcoming melanoma results and the company’s broader presence at ESMO 2026, one of the key oncology conferences. Merck/Moderna to Headline ESMO 2026
• Positive Sentiment: Oddo BHF raised its price target for Moderna to $251 from $170, adding to bullish sentiment and indicating that the firm sees greater potential in the company’s pipeline. Oddo BHF Adjusts Moderna Price Target
• Neutral Sentiment: Coverage also highlights Moderna as an artificial-intelligence and “biointelligence” healthcare investment, reflecting interest in data-driven drug development and testing but not a specific new operating announcement. The AI Trade Just Moved Into Your Bloodstream
• Negative Sentiment: A Seeking Alpha analysis argues investors should “sell the cancer vaccine hype,” warning that expectations surrounding the oncology program may have moved ahead of the evidence. The upcoming clinical readout therefore carries elevated downside risk if results disappoint. Moderna: Sell The Cancer Vaccine Hype
• Negative Sentiment: President Stephen Hoge and other company insiders reported stock sales, including transactions conducted under a trading plan. Planned sales do not necessarily signal deteriorating fundamentals, but they can weigh on sentiment after the sharp advance. Moderna’s Stephen Hoge Sells Shares Under Trading Plan

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Moderna in a research note on Wednesday, September 9th. Berenberg Bank boosted their price objective on shares of Moderna from $45.00 to $100.00 and gave the stock a “hold” rating in a research note on Friday, September 11th. Bradesco Corretora upgraded Moderna to an “outperform” rating in a report on Friday, August 28th. William Blair started coverage on Moderna in a research report on Friday, August 28th. They set an “outperform” rating for the company. Finally, Morgan Stanley lifted their target price on Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. Seven equities research analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and four have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $101.45.

Moderna Price Performance

The firm has a market cap of $96.65 billion, a price-to-earnings ratio of -30.30 and a beta of 1.09. The business’s 50-day simple moving average is $160.00 and its two-hundred day simple moving average is $92.42. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter last year, the business earned ($2.13) EPS. As a group, research analysts expect that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the transaction, the insider directly owned 74,129 shares in the company, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 197,251 shares of company stock worth $33,875,904. Company insiders own 10.80% of the company’s stock.

Institutional Trading of Moderna

Several large investors have recently modified their holdings of the stock. BlackRock Inc. bought a new stake in Moderna during the 2nd quarter valued at $2,142,877,000. Theleme Partners LLP bought a new position in shares of Moderna in the second quarter valued at $564,272,000. Wellington Management Group LLP lifted its stake in shares of Moderna by 4.4% in the second quarter. Wellington Management Group LLP now owns 2,461,574 shares of the company’s stock valued at $172,384,000 after buying an additional 103,977 shares in the last quarter. Merck & Co. Inc. bought a new position in shares of Moderna in the second quarter valued at $161,642,545. Finally, Bamco Inc. NY acquired a new position in shares of Moderna during the second quarter valued at about $139,317,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.